Upgrade to SI Premium - Free Trial

Seres Therapeutics (MCRB)

5.28 +0.03 (0.57%)

Chart
Today 6M 1Y 5Y

Upcoming Events

- Earnings (8/5/26)

Latest Headlines

Form 4 Seres Therapeutics, Inc. For: Jul 08 Filed by: Graves Kurt July 10, 2026 4:15 PM - SEC Filing Form 4 Seres Therapeutics, Inc. For: Jul 08 Filed by: Shaff Eric D. July 10, 2026 4:15 PM - SEC Filing Form 4 Seres Therapeutics, Inc. For: Jul 08 Filed by: Kender Richard N July 10, 2026 4:15 PM - SEC Filing Form 4 Seres Therapeutics, Inc. For: Jul 08 Filed by: Dere Willard H July 10, 2026 4:15 PM - SEC Filing Form 4 Seres Therapeutics, Inc. For: Jul 08 Filed by: Henn Matthew R July 10, 2026 4:15 PM - SEC Filing Form 4 Seres Therapeutics, Inc. For: Jul 08 Filed by: Ausiello Dennis A July 10, 2026 4:15 PM - SEC Filing Form 4 Seres Therapeutics, Inc. For: Jul 08 Filed by: Brady Kelly July 10, 2026 4:15 PM - SEC Filing Form 4 Seres Therapeutics, Inc. For: Jul 08 Filed by: Thorell Marella July 10, 2026 4:15 PM - SEC Filing Form 4 Seres Therapeutics, Inc. For: Jul 08 Filed by: Rosiello Robert L. July 10, 2026 4:15 PM - SEC Filing Form 4 Seres Therapeutics, Inc. For: Jul 08 Filed by: Fraser Claire July 10, 2026 4:15 PM - SEC Filing Form 4 Seres Therapeutics, Inc. For: Jul 08 Filed by: DesRosier Thomas July 10, 2026 4:15 PM - SEC Filing Form 4 Seres Therapeutics, Inc. For: Jul 08 Filed by: Berenson Stephen July 10, 2026 4:15 PM - SEC Filing Form S-8 Seres Therapeutics, Inc. July 9, 2026 4:06 PM - SEC Filing Form 8-K Seres Therapeutics, Inc. For: Jul 08 July 8, 2026 4:05 PM - SEC Filing Form 8-K Seres Therapeutics, Inc. For: Jul 08 July 8, 2026 8:00 AM - SEC Filing Seres reports early trial data for SER-155 in cancer therapy side effect July 8, 2026 7:01 AM - StreetInsider Seres Therapeutics Announces Early Clinical Data Showing Potential for SER-155 in Immune Checkpoint Inhibitor-Related Enterocolitis (irEC), a Frequent Adverse Reaction That Forces Many Patients to Hal July 8, 2026 7:00 AM - Globe NewsWire Form 4 Seres Therapeutics, Inc. For: Jul 01 Filed by: Berenson Stephen July 2, 2026 6:13 PM - SEC Filing Form 4 Seres Therapeutics, Inc. For: Jul 01 Filed by: Rosiello Robert L. July 2, 2026 6:10 PM - SEC Filing Form 4 Seres Therapeutics, Inc. For: Jul 01 Filed by: Ausiello Dennis A July 2, 2026 6:06 PM - SEC Filing Seres Therapeutics to Host Webcast on July 8, 2026, to Discuss Results of Investigator-Sponsored Trial of Seres’ SER-155 in Immune Checkpoint Inhibitor-Related Enterocolitis June 25, 2026 7:00 AM - Globe NewsWire H.C. Wainwright Starts Seres Therapeutics (MCRB) at Buy June 23, 2026 6:07 AM - StreetInsider Form 8-K Seres Therapeutics, Inc. For: Jun 02 June 5, 2026 7:05 AM - SEC Filing Seres Therapeutics secures $25 million from Nestle deal, cuts lease costs June 5, 2026 7:00 AM - StreetInsider Seres Therapeutics Announces Two Transactions to Strengthen Balance Sheet, Reduce On-Going Lease Costs and Extend Projected Operating Cash Runway Well Into the First Quarter of 2027 June 5, 2026 7:00 AM - Globe NewsWire Form 8-K Seres Therapeutics, Inc. For: May 30 June 1, 2026 4:33 PM - SEC Filing Form 144 Seres Therapeutics, Inc. Filed by: Young Teresa L. May 19, 2026 4:16 PM - SEC Filing Form 4 Seres Therapeutics, Inc. For: May 15 Filed by: Shaff Eric D. May 19, 2026 4:05 PM - SEC Filing Form 4 Seres Therapeutics, Inc. For: May 15 Filed by: Henn Matthew R May 19, 2026 4:05 PM - SEC Filing Form 4 Seres Therapeutics, Inc. For: May 15 Filed by: Brady Kelly May 19, 2026 4:05 PM - SEC Filing Form 4 Seres Therapeutics, Inc. For: May 15 Filed by: DesRosier Thomas May 19, 2026 4:05 PM - SEC Filing Seres Therapeutics to Participate in H.C. Wainwright 4th Annual BioConnect Investor Conference May 12, 2026 7:01 AM - Globe NewsWire Form 10-Q Seres Therapeutics, Inc. For: Mar 31 May 5, 2026 10:31 AM - SEC Filing Seres Therapeutics (MCRB) Misses Q1 EPS by 28c May 5, 2026 7:33 AM - StreetInsider Form 8-K Seres Therapeutics, Inc. For: May 05 May 5, 2026 7:05 AM - SEC Filing Seres Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Updates May 5, 2026 7:00 AM - Globe NewsWire Seres Therapeutics presents preclinical data for IBD drug candidate May 4, 2026 7:00 AM - StreetInsider Seres Therapeutics Presents Preclinical Data at Digestive Disease Week (DDW) 2026 Supporting SER-603, a Next-Generation Cultivated Live Biotherapeutic Candidate, for Inflammatory Bowel Disease May 4, 2026 7:00 AM - Globe NewsWire Form DEFA14A Seres Therapeutics, Inc. April 27, 2026 4:11 PM - SEC Filing Form DEF 14A Seres Therapeutics, Inc. For: Jun 09 April 27, 2026 4:06 PM - SEC Filing Full Article List